Rationale: The comparative efficacy and cost-effectiveness of constraint-induced and multi-modality aphasia therapy in chronic stroke are unknown.
Introduction and rationale
Aphasia, an acquired language disability, impacts understanding speech, reading, writing, and speaking. Aphasia affects one-third of stroke survivors, 1 with significant negative impacts on mental health 2 and quality of life. 3 People with stroke-aphasia vary widely in aphasia type and severity, and co-morbid cognitive impairments. This variability has underpinned the development of a range of aphasia treatments. In the recent Cochrane review, analysis of 57 aphasia therapy trials revealed statistically significant treatment effects for functional communication, reading, writing, and expressive language. 4 Significant benefits were found for high intensity, high dose, or long duration interventions, although these schedules had a larger drop-out rate. 4 Benefits were not maintained at three-to six-month follow-up. 4 The review results are limited by small numbers of randomized participants and inferior study quality. Recently, Breitenstein et al. compared intensive language therapy (30 h over 3 weeks) to usual care in 156 people with chronic (>6 months) post-stroke aphasia and found significantly improved verbal communication (d-0.58) immediately post-intervention and at six-month follow-up. 5 Constraint-induced aphasia therapy (CIAT) is an intensive, high-dose intervention aimed at improving verbal output in a group setting of two to three patients. 6 CIAT assumes that people with aphasia experience a worsening of symptoms through non-use of language and a reliance on nonverbal communication (e.g., gesture, drawing). Therefore, CIAT focuses on speaking activities and nonverbal communication is discouraged. CIAT-Plus is an enhanced protocol including written cues and home practice. 6 Multi-modality aphasia therapy (M-MAT) also aims to improve verbal output but specifically utilizes nonverbal strategies 7 that may be useful if speaking fails after treatment. Evidence from a pilot study 7 and a systematic review 8 suggest CIAT-Plus and M-MAT may be equally efficacious. However, high quality comparative-effectiveness evidence is required to refine treatment prescription and describe potential costeffectiveness.
Methods
The aims of the COMPARE trial are to determine whether CIAT-Plus and M-MAT are superior to usual care (UC) for people with chronic aphasia and determine if CIAT-Plus or M-MAT are superior for particular subgroups. The primary hypothesis is that compared to UC, both CIAT-Plus and M-MAT will result in reduced aphasia severity (5-point improvement on the Western Aphasia Battery-Revised Aphasia Quotient (WAB-R-AQ)) 9 immediately post-intervention. CIAT-Plus is predicted to be superior for moderate aphasia and M-MAT superior for both mild and severe aphasia. 7 The potential costeffectiveness of these interventions over UC is assessed.
Design COMPARE is a three-armed prospective, singleblinded multicenter, randomized controlled trial with primary outcome immediately following treatment and follow-up 12 weeks after treatment (see Figure 1 ) with an intention-to-treat analysis. The protocol is aligned with the CONSORT extension for non-pharmacologic interventions, 10 is registered with the Australian and New Zealand Clinical Trials Registry (12615000618550), and has ethics approval from La Trobe University, Gold Coast University Hospital (Queensland, Australia), and each participating hospital site's ethics committee.
Patient population-Inclusion and exclusion criteria
Stroke >6 months; aphasia severity categorized using WAB-R-AQ. See Table 1 for full details.
Randomization
Each participant is assessed for baseline aphasia severity, (WAB-R-AQ mild ¼ 93.7-62.6; moderate ¼ 62.5-31.3; severe < 31.2) and allocated to a group of two to three participants with the same severity level. Each group is randomized to one of three arms. The randomization schedule was created by an independent statistician, using a computer-generated permuted blocked procedure and allocation ratio of 1:1:1.
Intervention
CIAT-Plus and M-MAT interventions are provided by qualified, study-trained speech pathologists for 3 h per weekday for two weeks (30 h) with 15 min daily home practice tasks monitored via written log/carer report. All assessment staff are blinded to group allocation.
Arm 1: UC. The UC control group undergo aphasia therapy at the type and frequency available in the community at the time of recruitment and randomization (estimated at <2 h/week). Participants keep a studyspecific diary of therapy activity.
Arm 2: CIAT-Plus. In CIAT-Plus, participants produce functional words, phrases and sentences in response to pictured object and action cards in communication games. Visual barriers between participants discourage non-verbal communication. Therapists cue and shape verbal responses, providing verbal models to repeat and written words for participants to read aloud. As performance improves, participant responses are progressively shaped from single words (e.g., ''Coffee?'') to elaborated sentences (e.g., ''John, do you want a large, black coffee?''). 
Primary outcome
Required study assessments with timelines are outlined in Figure 1 . The primary outcome is the WAB-R-AQ score assessed by a blinded assessor immediately postintervention. The WAB-R-AQ is a reliable measure of language impairment, is sensitive to change, and forms a recommended core outcome for aphasia intervention trials. 9, 12 Secondary outcomes Secondary outcomes include: aphasia severity (WAB-R-AQ 9 score at 12-week follow-up); health-related quality of life (SAQoL-39, 13 EQ-5D-3L 14 ), multimodal communication (Scenario Test 15 ) and functional communication (Communication Effectiveness Index 16 ) immediately and at 12 weeks post-intervention. A resource use and cost questionnaire is collected at 12-week follow-up.
Data monitoring body
Participants are monitored for adverse events (AEs) throughout this trial. AEs relating to a new diagnosis or worsening of clinical symptoms are reported up to the follow-up assessment. An independent Data Safety Monitoring Committee reviews safety data annually (or earlier if necessary).
Sample size estimates
After adjusting for the clustering effect of group therapy, 216 participants will provide 90% power to detect a 5-point difference on the WAB-AQ at a ¼ 0.05.
Statistical analyses
Separate linear mixed models (LMMs) will be used to analyze differences between M-MAT and UC, and CIAT-Plus and UC on each outcome measure immediately and at 12 weeks post-intervention. The LMM for WAB-R-AQ will assess the differences in efficacy between M-MAT and CIAT-Plus. All analyses will control for baseline aphasia severity (fixed effect) and for the clustering effect of treatment groups (random effect). Details will be published in a formal statistical analysis plan, prior to trial completion.
Economic evaluation
Resource utilization is captured using a standardized approach from a societal perspective with the main focus on the health sector and costs to individuals. Costs involved in the organization and delivery of the Uncorrected sensory loss preventing participation in communication assessments and treatments Serious medical condition prior to their stroke (including malignancies, psychiatric, behavioral or drug-dependency problems) likely to influence participation or prevent adherence to protocol intervention are included. Incremental cost-effectiveness ratios will be reported as the net cost per unit improvement in the primary and secondary outcomes. Sensitivity and uncertainty analyses will be undertaken.
Study organization and funding
The COMPARE trial is managed by the management committee comprising all chief investigators and trial managers and supported by a National Health and Medical Research Council Project grant (#1083010).
Summary and conclusion
COMPARE is the first trial to assess the comparative efficacy of constraint induced and multi-modal aphasia therapies for chronic post-stroke aphasia. Results will enable more effective treatment prescription. Cost-effectiveness information will provide support for business cases in adapting current management practice and policy for chronic aphasia. Since trial commencement, 135 participants have been randomized.
